Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority
Silver Spring, Maryland—(ENEWSPF)—May 17, 2018
By: Michael Felberbaum
The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. While Lucemyra may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only…
